Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX trial in residual triple-negative breast cancer
2018-002077-21Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ceralasertib, olaparib and durvalumab in triple-negative breast cancer (TNBC) and breast cancer (7 cohorts), sponsored by The Institute of Cancer Research. Primary endpoint: Cohort-specific biological activity endpoint. Status: unknown.
02
Drugs
ceralasertibolaparibdurvalumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2018-002077-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002077-21.